Artivion Seals Endospan Deal, Bringing NEXUS Aortic Arch System Fully In‑House

Artivion, Inc. (NYSE: AORT) has completed its acquisition of Endospan Ltd., bringing the FDA‑approved NEXUS Aortic Arch System fully in‑house and strengthening its position in complex aortic repair. The move fits Artivion’s strategy to build a comprehensive aortic portfolio that covers open, hybrid, and endovascular procedures.

What Artivion Is Getting

Endospan, based in Israel, develops endovascular devices for aortic arch disease, led by the NEXUS Aortic Arch System, which recently received U.S. FDA Premarket Approval. With closing complete, NEXUS and Endospan’s pipeline now become part of Artivion’s cardiac and vascular surgery product family.

Deal Structure in Brief

Artivion is paying a $175 million all‑cash base purchase price, with an estimated ~$135 million net upfront after offsetting loans it had previously extended to Endospan. The agreement also includes up to $200 million in contingent earn‑outs tied to future NEXUS performance, and the upfront is funded mainly through Artivion’s existing term loan facility.

Strategic Rationale

By integrating NEXUS with its existing offerings like AMDS and future platforms such as Arcevo LSA, Artivion aims to be a one‑stop shop for aortic arch repair solutions. This deal deepens its presence in advanced endovascular therapies and could improve growth and differentiation in a high‑acuity, under‑served area of cardiovascular care.

Investor Snapshot

For investors in Artivion (AORT), the acquisition offers meaningful upside but also higher leverage and execution risk. Success will depend on physician adoption of NEXUS, training and reimbursement progress, and Artivion’s ability to grow revenue and margins enough to justify the added debt and potential earn‑outs.